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   I 
Preface 
In the process of finding a project for my master thesis, I asked professor Arthur Revhaug if 
he had any ideas for a project. Professor Revhaug proposed to investigate the risk of Venous 
Thromboembolic (VTE) complications associated with short-term antithrombotic 
prophylaxis, used at University Hospital of North Norway (UNN) between 2013 and 2018, 
following resections of malignant tumors in the upper part of the abdomen. 
  
This project has been supervised by Professor Arthur Revhaug and Consultant Surgeon Eirik 
Kjus Aahlin. Professor Revhaug supervised the recording of the data and contributed in the 
process of defining the project, with inclusion and exclusion criteria. Consultant Surgeon 
Aahlin supervised the process of organizing the data and writing the thesis. I would like to 
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Abstract 
Background: Venous thromboembolism (VTE) is a serious and potentially fatal 
complication after surgery. Operations for malignancy in the upper abdomen are traditionally 
regarded as especially prone to such complications. Antithrombotic prophylaxis with low 
weight molecular heparing (LWMH) before and after surgery has been shown to significantly 
reduce the risk for VTE complications. Recommended duration of antithrombotic prophylaxis 
after abdominal cancer surgery is 28 days. Many clinicians argue that antithrombotic 
prophylaxis until the patient is fully mobilized is sufficient. The primary object of this thesis 
was to investigate the safety of short-term antithrombotic prophylaxis and the risk of 
developing VTE after major upper abdominal cancer surgery.  
Method: This was a retrospective study of 493 patients undergoing elective surgery for 
cancer in the eosophagus, stomach, pancreas, liver, gallbladder and biliary tract at University 
Hospital of North Norway (UNN) Tromsø between 2013 and 2018. Patients which had a VTE 
while receiving antithrombotic prophylaxis, received antithrombotic prohpylaxis for more 
than 28 days, died within 90 days, were anticoagulated with vitamin K antagonists, LMWH or 
new oral anticoagulants before surgery, underwent minor surgery or were transferred to 
another hospital while still receiving antithrombotic prophylaxis, were excluded. Main 
outcome was symptomatic VTE diagnosed within 90 days after surgery.  
 
Results: A total of 243 patients were excluded from the main study group. For the remaining 
250 patients, five had a non-fatal VTE incident within 90 days of surgery (2%).  
 
Conclusion: Five out of 250 patients (2%) who received antithrombotic profylaxis for less 
than 28 days suffered from VTE complications within 90 days after surgery. This study 
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Abbreviations:  
- VTE: Venous thromboembolism 
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- RCT: Randomized controlled trial 
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- EHR: Electronic Health Record 
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1 Introduction 
1.1 Background 
VTE, including deep venous thrombosis (DVT) and pulmonary embolism (PE), are serious 
complications after many surgical procedures (1, 2). DVT occurs most often in the lower 
extremity. PE is an obstruction of the pulmonary artery or its branches by thrombus. The most 
common source of thrombus in the pulmonary artery is an embolization from the deep veins 
in the leg (3). PE is one of the most common preventable causes of in-hospital death 
following surgery. In general, the overall risk of VTE after surgery ranges from 0.5-1.6 % (4). 
For patients with underlying malignancy the risk is even higher (up to 3.7 %) (4, 5). Patients 
who undergo surgery for malignancy in the abdominal cavity are traditionally regarded as 
especially prone to VTE (6-8). Administration of LMWH subcutaneously (sc) before and 
after the surgical procedure has been shown to significantly reduce the risk of VTE (9). 
 
The guidelines for pre- and postoperative antithrombotic prophylaxis varies significantly 
depending on baseline risk for VTE. Using the Caprini score (10), patients can be divided into 
different groups depending on their risk of developing VTE. Modified Caprini risk 
assessment is illustrated in Figure 1.  
 
- Caprini score 0:  Very low risk. 
- Caprini score 1-2:  Low risk.  
- Caprini score 3-4: Moderate risk.  
- Caprini score  5: High risk.  
 
All patients undergoing major abdominal cancer surgery, have a Caprini score  4 (2 points 
for major or laparoscopic surgery > 45 mins and 2 points for present malignancy), and thus 
they are at moderate baseline risk for VTE, even without additional risk factors.  
 
For patients with moderate risk and no contraindications, it is suggested to use pharmacologic 
prophylaxis rather than mechanical methods, such as compresssion stockings (4). LWMH is 
generally considered the preferred anticoagulant, based upon randomized trials that report 
superior or similar efficacy with unfractionated heparin (UFH), while being easier to 
administer and follow-up (11). 
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The reason for the increased risk of VTE after surgery is complex, especially in patients with 
cancer. Individuals with cancer are at risk for thrombotic events due to a hypercoagulate state. 
The pathogenesis of the hypercoagulable state in malignant diseases involves multiple factors. 
Some examples are listed below (12):  
- Tumor specific factors: some tumor cells express procuagulant activity that can 
directly induce thrombin.  
- Anatomic factors: some tumor increase VTE risk by externally compressing or 
directly invading large vessels.  
- Patient-specific factors: VTE risk is increased in patients with prior VTE, advanced 
age, obestiy etc.  
- Therapy-assosiated factors: Several chemotherapy regiments, bed rest and major 
abdominal surgery. 
 
A review of 43 808 resections for malignant disease from the American College of Surgeons 
National Surgical Quality Improvement Program (ACS NSQIP) database (13), found that the 
risk of VTE was highest in patients undergoing esophagectomy (6.3%), followed by 
cystectomy, pancreatectomy, gastrectomy and colectomy. Patients with glucocorticoid steroid 
medication, advanced age ( 60), morbid obesity (BMI  35), blood tranfusion, reintubation, 
cardic arrest, postoperative infection complications and prolonged hospitalization were 
independently associated with increased risk of VTE.  
 
In another review of 44 656 patients from the ACS NSQIP database (14), the following 
factors were associated with increased risk of VTE:  
- Age  65 
- Metastatic disease 
- Ascites 
- Congestive failure 
- BMI  25 kg/m2 
- Platelet count > 400 × 109/L 
- Serum albumin < 3 g/dl 
- Duration of surgery > 2 hours 
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In the review, 1/3 of the VTE events occurred after hospital discharge and 30-day mortality 
was more than six-fold higher in patients with VTE compared to patients without VTE (8.0 vs 
1.2 %) (14). VTE is associated with increased morbidity and mortality in cancer patients (15). 
However, data to support improvement in mortality by using anticoagulation is lacking (12).  
 
A meta-analysis of eight Randomized Controlled Trials (RTCs) with five different 
preparations of LMWH that included > 48 000 general and abdominal surgery patients found 
that, compared with no prophylaxis, LWMH reduced the risk of symptomatic VTE by 70 
percent, but also caused a two-fold risk  of major bleeding and wound hematomas (16).   
 
The optimal duration of postoperative anticoagulation in patients with cancer is unknown, but 
it is likely to be longer than for patients without cancer (12). Cancer-assosiated VTE is a 
common condition, but the incidence varies widely depending on multiple factors like patient 
population, cancer types and stages, patient-related factors and certain cancer therapies. The 
reported risk varies between 1-8% (17, 18). One RCT investigating the efficacy and safety of 
four weeks compared to one week administration of antothrombotic prophylaxis following 
major abdominal surgery, showed significantly reduced rates of VTE with 4 weeks 
prophylaxis, without increased risk of bleeding (7).  
 
For most patients where antithrombotic prophylaxis is indicated, experts agree that 
pharmacological agents should ideally commence within 2-12 hours preoperatively (4). 
Generally, anticoagulation is continued daily for 10 to 12 days. 28 days is often considered 
reasonable for patients undergoing major abdominal or pelvic surgery (19). International and 
national guidelines generally recommend that postoperative administration of LMWH should 
last for 28 days after cancer operations in the abdomen (20-22). 
 
Over the last years, important changes have been implemented in perioperative protocols 
which may lower the incidence of postoperative VTE after abdominal cancer surgery. Two of 
the most important factors are the introduction of Enhanced Recovery After Surgery (ERAS) 
protocols and the introduction of minimally invasive techniques (23, 24). These factors may 
reduce the thrombogenic insult, as the recovery of patients becomes faster and procedures are 
less invasive.  
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VTE prophylaxis guidelines used today are mostly based on studies from before ERAS and 
minimally invasive techniques were implemented. Thus, many clinicians argue that these 
factors reduce the probability of developing clinically significant VTE, and hence administer 
LMWH prophylaxis routinely for 5-7 days or until the patients are fully mobilized and 
ambulatory, on their way home. Even though this practice may seem logical, it has not been 
studied in more than one RCT, to our knowledge (25).  
 
Randomized trials (7, 8, 25) have shown that four weeks duration antithrombotic prophylaxis 
with LWMH, decrease the risk of asymptomatic DVT by 50-60% without increasing the risk 
of postoperative bleeding compared to short-term prophylaxis. None of the studies disclosed a 
reduction in symptomatic DVT, symptomatic PE or VTE-related death.  
 
One large cohort study from Denmark has recently shown administration of short-term 
antithrombotic prophylaxis seems safe for colo/rectal cancer surgery when the patients follow 
the ERAS programme (24). This study showed that the risk of symptomatic VTE after 
uncomplicated, elective surgery for colon cancer with ERAS seemed negligible. However, a 
recent large retrospective review of the NSQIP database (2005-2013) focusing on patients 
with gastric, colorectal, pancreatic, and gynecologic malignancies still argue that there are 
several conditions of abdominal operations that seems to benefit from prolonged prophylaxis 
(26).  
 
A review of seven RCTs comparing prolonged thromboseprophylaxis ( fourteen days) with 
any LWMH agent with placebo or thromboseprophylaxis during admission only, found the 
incidence of overall VTE after major abdominal or pelvic surgery was 13.2% in the control 
group compared to 5.3% in the patients receiving out-of-hospital LMWH (27). The incidence 
of symptomatic VTE was 1% and 0,1% respectively.   
 
The efficacy of prolonged antithrombotic prophylaxis (four weeks) with LWMH in patients 
undergoing hip or knee replacement, have been documented by meta analysis (28). These 
patients are arguably more immobilized after surgery, and application to a different 
population is questionable.  
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1.2 Aim 
Traditional practice at UNN has been prolonged LMWH prophylaxis for 28 days after 
elective abdominal cancer surgery. For several years (including 2013-2018), patients 
undergoing abdominal cancer surgery at UNN received the first dose of LMWH the night 
before surgery and prophylaxis was generally continued until full mobilization or discharge 
(short duration).  
 
The amount of research on prolonged antithrombotic prophylaxis is limited, especially in 
terms of number of randomized controlled trials (RCTs). The primary objective of this thesis 
was to thoroughly investigate the effect of short duration LMWH prophylaxis on the risk of 
developing VTE after major abdominal cancer surgery. The primary outcome was 
symptomatic VTE confirmed by ultrasound or CT within 90 days after surgery.  
 
2 Method  
The investigation was a retrospective cohort study of patients who underwent major 
abdominal cancer surgery in the upper abdomen at the Gastrointestinal Surgery Department at 
UNN, in the period from 2013 to 2018.  
 
Major cancer surgery in the upper abdomen includes esophageal, gastric, pancreatic and 
major hepatobiliary cancer surgery (thus excluding colorectal cancers). Hence, patients who 
underwent a gastrointestinal surgical procedure corresponding to the following NCSP NCMP: 
JCC, JDC, JDD, JJB4, JJB5, JJB6, JJB1, JJB2, JJB3, JJB7, JJB9, JJB00, JJB01, JLC0, JLC1, 
JLC2, JLC3, JLC4, JLW96, JLW97 and ICD-10 codes C15, C16, C17, C22, C23, C24, C25, 
C78 were included. Only elective resections were included.  
 
UNN has allocated resources for retrieving, pre-processing, and making available electronic 
health record (EHR) data from the Department of Gastrointestinal Surgery for the years 2004-
2018 via the research project entitled QUAKE: Quality control of medical performance with 
unstructured EMR data (HST1194-14). This huge, longitudinal data set is referred to as the 
QUAKE database. The 493 patients included in this cohort were identified using the QUAKE 
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database. In order to adress the objective, the investigator used the electronic health record 
system for UNN (DIPS) to investigate the patients in the cohort. 
 
For all patients, the following data were collected: diagnosis and procedure code, use of 
antithrombotic medications before the surgery, number of days receiving antithrombotic 
prophylaxis, and number of days being hospitalized. In this process, patients that were 
diagnosed with VTE using standard methods, were identified. Standard methods include e.g. 
diagnosing symptomatic DVT by Doppler ultrasound or PE by CT pulmonary angiography. 
In addition, reoperation and deaths were recorded. A qualitative assessment was performed 
for the patients that had a VTE incident within 90 days of surgery.   
 
All of the UNN hospitals have a manual system for handling and documenting the patient´s 
in-hospital medication. Therefore, to register the number of days each patient received 
Dalteparin or other LWMH, handwritten and scanned medication lists used by the nurses in 
the ward, had to be examined.  
 
Out of 493 patiens, a total of 243 patients were excluded from the study. These patients were 
excluded due to the following criteria’s (Figure 2):  
1. Patients that had a VTE incident within 28 days of surgery, while receiving 
antithrombotic prophylaxis. There were five patients in this group.  
2. Patients that were transferred to a hospital outside the UNN system while still 
receiving antithrombotic prophylactic treatment. There were 120 patients in this 
group.  
3. Patients receiving antithrombotic prophylaxis for more than 28 days. There were 41 
patients in this group. Most of these patients had a complicated postoperative course 
and were immobilized for longer than 28 days or had multiple established risk factors 
for VTE.  
4. Patients that died within 90 days after surgery. There were 8 patients in this group.  
None of these died from VTE related complications.  
5. Patients already being treated with Vitamin K antagonist, LWMH or new oral 
anticoagulants before surgery and with continued treatment afterwards. Patients that 
started using these drugs in the postoperative course due to non-VTE related 
complications were also excluded. There were 38 patients in this group.   
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6. Patients that did not undergo major abdominal surgery, but minor procedures like 
placement of central venous catheter or needle biopsy. There were 25 patients in this 
group.  
 
Also, six patients were excluded because the list of medication while hospitalized was not 
scanned into their medical records.  
 
Patients who used platelet aggregation inhibitors, such as aspirin or clopidogrel, were not 
excluded because VTE prophylaxis is not an indication for these drugs (24). 
 
Ultimately the study group included patients that underwent major cancer surgery in the upper 
abdomen at UNN Tromsø between 2013 and 2018, that were discharged or transferred to a 
local hospital within 28 days without prolonged antithormbotic prophylaxis (n = 250). 
  
Use of the QUAKE-database for quality control is granted by REK (2012/2127) and The 
Norwegian Center for Research Data (NSD). The Data Protection Official at UNN HF 
granted permission for this internal control and quality assesment after Helsepersonelloven 
§26 and informed consent was not be required for this work.  
 
3 Results 
In the study group, 124 patients underwent laparoscopic resections. The median length of 
antithrombotic prophylactic treatment amongst these patients was seven days. 126 patients 
underwent open resections. The median length of antithrombotic prophylactic treatment 
amongst these patients was 12 days. Most of the patients received Dalteparin 5000 IU sc, but 
a few patients received Enoksaparin 40 mg sc.  
 
The dispersion of tumor localization in the study group was as following:  
- Esophagus: 24. 
- Stomach: 59.  
- Liver metastasis, mostly from colorectal cancer: 85. 
- Primary liver tumor: 21. 
- Biliary tract and gall bladder: 9.  
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- Pancreas: 41. 
- Unspecified: 11.  
 
Five patients that were discharged within 28 days of surgery without prolonged prophylaxis 
had a symptomatic VTE within 90 days. None of the incidents were fatal. All of these patients 
except one underwent open surgery. All of the patients were treated with anticoagulants for a 
minimum of 3 months after being diagnosed with VTE. Three of the patients had a PE (1,2%) 
 
Qualitative assessment of these patients:  
- Patient 1: 73 years old female, no prior history with VTE, no known cardiovascular 
disease. She underwent a laparoscopic resection of multiple lever segments after being 
diagnosed with metastatic colon cancer. The surgery was uncomplicated. 
Postoperative she had episodes with dyspnea, desaturation and low pO2. She went 
through a CT angiogram while hospitalized, but no PE was discovered. She received 
Dalteparin 5000 IU sc for a total of five days, starting the night before surgery. Six 
weeks after the surgery, she started adjuvant chemotherapy. Approximately two 
months after the surgery, she had repeated episodes of chest pain and dyspnea. She 
was hospitalized for an ultrasound of the heart that revealed cor pulmonale. CT did not 
show any sign of present PE, but she was diagnosed from the clinical picture and 
echocardiographic findings.  
- Patient 2: 75 years old female. No prior history of VTE. Medically treated for 
hypertension, otherwise no known cardiovascular disease. Used Albyl-E 75 mg once 
daily prior to the surgery, uncertain indication. She underwent an open transhiatal 
esophagectomy. The surgery was uncomplicated. Postoperative she got atrial 
fibrillation and was treatet for three days in the intensive care unit with Cordarone. 
She also had a therapeutic thorascentesis due to symptomatic pleural effusion. She 
received Dalteparin 5000 IU sc for 16 days, starting the night before surgery. She was 
fully mobilized at the postoperative day seven. She was readmitted to the hospital 23 
days after surgery with dyspnea and hypoxia and was diagnosed with bilateral PE 
using CT angiogram.  
- Patient 3: 53 years old male. No prior history of VTE. No cardiovascular disease. He 
used Albyl-E before the surgery, the indication was uncertain. He underwent an open 
transthoracic esophagectomy removing a distal tumor in the esophagus. The surgery 
 
Page 9 of 24 
was uncomplicated, but the tumor was bigger than expected and they had to do a total 
gastrectomy and cholecycstectomy. Postoperative the patients had a lot of pain, but 
otherwise the postoperative course was relatively uncomplicated. He received 
Dalteparin 5000 IU sc for 11 days, starting the night before surgery. He was diagnosed 
with a PE using CT angiogram 28 days after surgery.  
- Patient 4: 55 years old male. No prior history of VTE. He used antihypertensive 
medication, otherwise no known cardiovascular disease. He underwent an open 
pancreatectomy and resection of the stomach. The procedure and postoperative course 
were uncomplicated. He received Dalteparin 5000 IU sc for 8 days, starting the night 
before the surgery. More than two months after the surgery he was admitted with 
stomach pain. CT scans from approximately 1,5 months after the surgery showed a 
thrombose in the portal vein and new CT scans showed an even bigger thrombus that 
involved the mesenteric veins.  
- Patient 5: 71 years old female. No know cardiovascular disease, no prior history of 
VTE. She underwent an open resection of a tumor in the lever, suspected to be 
recurrence of previously treated HCC. The procedure and the postoperative course 
were uncomplicated. She received Daltaparin 5000 IU sc for three days, starting the 
night before the surgery. She experienced swelling and pain in her right foot 35 days 
after the surgery, and CT venography revealed thrombosis from the vene cava inferior, 
to vena tibialis posterior.  
 
Four patients had a VTE incident while being hospitalized and still receiving antithrombotic 
prophylaxis. These patients were excluded from the study group, but the assessment of these 
patients is described below as it highlights the complexity of thromboembolic complications. 
Two of these patients had esophageal cancer, one had metastatic colon/rectal cancer, one had 
Hepatocellular carcinoma (HCC) and one had pancreatic cancer. These patients were treated 
according to national guidelines in regards of antithrombotic profylaxis and received 
treatment for the VTE with higher doses of anticuagulants after diagnosis.  
 
Qualitative assessment of these patients:  
- Patient 6: 56 years old male. No prior history of VTE. Known COPD. He had 
neoadjuvant chemotherapy before the surgery. He used Albyl-E 75 mg daily before 
the surgery after having a cerebrovascular incident three months before surgery. He 
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underwent transhiatal esophagectomy for an adenocarsinoma in the gastroesophageal 
junction (GEJ). He had a reoperation five days postoperative for wound dehiscence. 
He was intubated for several days. He received Dalteparin 5000 IU sc until he was 
diagnosed with PE on day 15 postoperative.  
- Patient 7: 68 years old male. No prior history of VTE. Hypertension and diabetes 
mellitus type II. He underwent an open surgery for a pancreatic tumor that had locally 
advanced into the portal vein. He got multiple GoreTex grafts perioperative. He 
received Dalteparin 5000 IU sc x 2 daily. Six days after the surgery, he was reoperated 
due to abdominal pain and the GoreTex graft was occluded. A trombus was also 
discovered above the graft in the portal vein.  
- Patient 8: 54 years old male with cancer coli with metastasis to the lever. He 
underwent an open lever segment resection. The procedure was uncomplicated, but 
postoperative he had a pneumothorax. The second day after the surgery his lactate 
levels were rising. He had a CT angiogram, but no PE was confirmed. He received 
Dalteparin 5000 IU sc daily. Day six postoperativ he had another CT angiogram that 
confirmed a suspected PE.    
- Patient 9: 68 years old male with cancer sigmoideum with liver metastasis. He 
underwent an open lever segment resection. He received Dalteparin 5000 IU sc for 
five days, then Enoksaparin 40 mg sc for 21 days. He was diagnosed with DVT two 
and a half months after the surgery.  
 
In addition, three patients that were anticuagulated with Vitamin K antagonists, LWMH or 
new oral anticoagulants prior to the cancer diagnosis and thus were excluded from the study 
group, had a VTE incident while hospitalized. Two of these patients had prior history of PE. 
They were given Dalteparin 5000 IU sc daily as antithrombotic prophylaxis until they were 
diagnosed with PE. The last patient was anticoagulated with 100 mg Enosaparin x 2 daily 
before the surgery and received Dalteparin 5000 IU once daily while hospitalized. He was 
diagnosed with a thrombus in v. jugularis interna 13 days postoperative.  
 
Two patients that underwent minor surgery and thus were not included in the study group, 
had VTE complications within 90 days. One patient had a symptomatic DVT 26 days after an 
ERCP. The other patient had a symptomatic DVT 4 days after a needle biopsy in the liver. 
Both of these patients had hepatocellular carsinoma.  
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In this study group 8% of the patients that underwent a resection of the esophagus, 1% of the 
patients that underwent a liver segment resection for metastatic colorectal cancer, 5% of the 
patients that underwent a pancreatectomy and 2% of the patients that underwent a liver 
segment resection for HCC had a VTE incident within 90 days of surgery (Table 1).  
 
4 Discussion 
In this retrospective cohort study of elective surgery for cancer in the upper abdomen with 
antithrombotic prophylaxis for 28 days or less, VTE occurred in two percent of the 250 
patients. These five incidents occurred in patients that received prophylaxis for 3-15 days 
after surgery. None of these patients had prior history of VTE or other established risk factors 
for VTE, other than age, present cancer and major surgery.  
 
One percent of the patients in the study group that underwent laparoscopic surgery had a VTE 
incident (1/124) and three percent of the patients that underwent an open surgery had a VTE 
incident (4/126). The numbers in this study group are small. Still, this might indicate that 
there is a difference in risk of VTE for open and laparoscopic surgery. A significant 
difference has been reported in multiple larger studies (29-32).  
 
The median duration of prophylaxis in this cohort was 12 days. Two percent of the patients 
that received short-term antithrombotic prophylaxis had a symptomatic VTE incdence within 
90 days of surgery. In comparison, the Cochrane review found an incidence of 1% of VTE 
complications within 30 days in patients that received short-term antithrombotic prophylaxis 
(27).  
 
The period of follow-up in was 90 days in this study. The longer the follow-up, the higher the 
risk of other factors contributing (e.g. chemotherapy). At least one of the patients which had 
an VTE incident within, 90 days received adjuvant chemotherapy in this period. The long 
follow-up period might contribute to a higher incidence of symptomatic VTE than in the 
Cochrane review. 0,8 percent of the patients in this study, had a VTE incident within 30 days 
of surgery.  
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The incident of VTE after major abdominal surgery found in studies varies greatly. Vendler 
et. al. found an incident of 0,2% of VTE in patients that underwent colorectal cancer surgery 
and receiving antithrombotic prophylaxis until discharge and following the ERAS programme 
(24). Vedovati et al. found VTE in 9,27% of the patients receiving antithrombotic prophylaxis 
for only one week after laparoscopic colorectal cancer surgery (25). Rasmussen et al. found 
the incidence of VTE to be 16,3% in patients that underwent open abdominal surgery (7). 
Both Vedovatis and Rasmussens studies also disclosed asymptomatic DVT, thus giving a 
higher incident than other studies. Henke et al. found an overall VTE risk of 2,2% within 30 
days for patients undergoing colectomy (6).  
 
All the patients with an VTE incident in the study group, underwent either esophagectomy, 
pancreatectomy or liver segment resection. Non of the patients that underwent resection of the 
stomach or tumors in the biliary tract/gallbladder had a VTE incident. This might indicate that 
esophagal cancer, pancreatic cancer and liver metastasis from colorectal cancer might be 
associated to a higher risk of VTE compared to stomach, gallbladder and biliary tract cancer. 
Due to the small numbers in the study group, the correlation might also be a coincidence and 
is not significant. More studies are required to affirm a significant correlation.  
 
Some factors contributing to this variation might be related to the different surgical 
techniques used for different localization, difference in tumor characteristics etc. Removal of 
tumors in the pancreas and esophagus are complicated procedures that are usually preformed 
as open surgery, while e.g. removal of the stomach is more often done laparoscopic. 
Metastatic disease is known to increases the risk of VTE (13, 14).  
 
This study has several limitations. As a result of the retrospective design, some cases of VTE 
might have been missed. In Norway, all acute cases of suspected VTE is usually diagnosed 
and treated at the public hospitals. In the study group, a number of the patients have a 
different hospital than UNN as their local hospital. When the VTE incident is believed to be a 
complication of the surgery, this is registered in the patient’s health record. There is still a 
possibility that some patients had a VTE within 90 days and this was not reported as a 
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Since there is not yet an electronic system for handling everday in-hospital medications at 
UNN, the number of days patients received LWMH might be inaccurate. The scanned lists of 
given medication were from the nurses at the ward. Some days it was not registrered that a 
patient received LWMH. It is impossible to know if the nurses forgot to give the patient 
LWMH or if they forgot to sign the medication list. Hence, the number of days registrered 
might not be correct in some patients.  
 
There have been several RCTs comparing 4 weeks duration of antithrombotic prophylaxis to 
1 week (7, 24, 25), but all of these disclosed asymptomatic VTE incidents. The morbidity and 
mortality related to asymptomatic VTEs is not fully certain, but one mortality risk analysis of 
patients with metastatic colorectal cancer found a longer survival for patients with 
asymptomatic VTE than in patients without VTE (33). This suggest that the significance of 
asymptomatic VTE is small. Therefore, it would be valuable to do an RCT comparing four 
weeks versus one week of antithrombotic prophylaxis in patients having major abdominal 
cancer surgery where end point is symptomatic VTE. Ideally, such an RCT should be 
stratified on open and laparoscopic surgery.  
 
In 2019, the Gastrointestinal Surgery Department at UNN changed the duration of 
antithrombotic prophylaxis. Today, all patients undergoing surgery for malignancy in the 
abdomen, receive a minimum of 14 days of antithrombotic prophylaxis.  
 
5 Conclusion 
Out of 250 patients that received short-term antithrombotic prophylaxis after cancer surgery 
in the upper part of the abdomen at UNN Tromsø between 2013 and 2018, two percent had a 
VTE incident within 90 days after surgery. In this study group, the overall risk of VTE was 
highest for patients that underwent esophagectomy. This study highlights the importance of 
sufficient length of VTE prophylaxis and is in accordance with other major studies  
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Figure 1: Caprini risk assessment model (34) 
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Figure 2: Patients excluded from the study group  
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8 Tables 
 
Type of resection (n) VTE n (%) 
Esophagus (24) 2 (8) 
Stomach (59) 0 (0) 
Hepatic metastasis (85) 1 (1) 
Primary hepatic tumor (21) 1 (5) 
Biliary tract and gallbladder (9) 0 (0) 
Pancreatic (41) 1 (2) 
Unspesified (11) 0 (0) 
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Studiedesign:  RCT                                
Grade - kvalitet   Strong 
Formål Materiale og metode Resultater Diskusjon/kommentarer/sjekkliste 
To evaluate the 




administered for 28 
days after major 
abdominal surgery 
compared to 7 days 
treatment.  
Inklusjons-/eksklusjonskrit. 
Patients were eligible for inclusion in the study provided they 
were hospitalized for major abdominal surgery, gave written 
informed consent to participate in the study, and were over 18 
years old. Major surgery was defined as an open abdominal 
surgical intervention in the gastric tract, the biliary system, 
pancreas, or intestine, as well as explorative laparotomy. The 
duration of the planned surgical procedure was more than 1 h. 
The exclusion criteria were severe peripheral arterial 
insufficiency (absence of a palpable pulsation in the dorsalis 
pedis artery), pregnancy, allergy to radiographic contrast 
medium, acid sulfite or LMWH, hepatic insufficiency, acute 
stroke within the last 3 months, gastrointestinal bleeding 
within the last month, hemorrhagic diathesis, anticoagula- tion 
treatment (including heparin, and vitamin K antago- nists, but 
not antiplatelet treatment), treatment with dextran, psychosis 
or severe dementia, simultaneous participation in another 
clinical study, or previous participation in the present study.  
 
Datagrunnlaget 
590 patients were recruited, 427 patients were randomized and 
343 patients reach an evaluable endpoint. 222 were 
randomized to short-term thromboprophylaxis and 205 to 
prolonged thromboprophylaxis.  
All patients received standard thromboprophylaxis with once-
daily s.c. dalteparin, 5000 IU, and wore graduated 
compression stockings for 7 days. Patients scheduled for 
abdominal surgery were enrolled in the study and randomly 
assigned to receive either no further treatment after day 7 
(short-term thromboprophylaxis group) or prolonged 
administration of once-daily dalteparin, 5000 IU s.c., for a 
further 21 days (prolonged thrombo-prophylaxis group).  
 
Utfall (outcome) validering 
The primary efficacy endpoint was objectively verified VTE 
occuring between 7 and 28 days after surgery. All patients 
underwent bilateral venography at day 28.  
 
Eksponeringsvariabler (validert/ikke validert) 
Viktige konfunderende faktorer  
The patients in the two treatment arms were well matched for 
age, sex, weight, previous VTE, and previous cancer (Table 
1). The types of surgical procedure were similar in the two 
groups, colorectal resection being the most common.  
 
Statistiske metoder 
The chi-squared test was used for comparing binominal data, 
and the Mann–Whitney U-test for continuous data. The level 
of significance was taken as less than 0.05. For the estimation 
and interpretation of differences between the two groups in 
rates of VTE, 95% confidence intervals (CIs) were calculated. 
The statistical software used was SPSS for Win- dows, 
version 8.0 (SPSS Inc., Chicago, IL, USA). The occurrence of 
VTE was analyzed on an intention- to-treat (ITT) basis.  
Hovedfunn 
The cumulative incidence of VTE was 
reduced from 16.3% with short-term 
thromboprophylaxis (29/178 patients) to 
7.3% after prolonged 
thromboprophylaxis (12/ 165). The 
number that needed to be treated to 
prevent one case of VTE was 12 (95% 
confidence interval 7–44). Bleeding 




Hvor stor er «intervensjons-
effekten»?  
Relative risk reduction for overall VTE 
with 4 weeks prophylaxis was 55% 
(95% confidence interval 15–76; p 
0.012).  
Relative risk reduction for DVT with 4 
weeks prophylaxis was 51% (95% 
conficence iterval 6-74; p 0.027).  
 
Bifunn – andre viktige endepunkter 
Major and minor bleeding events were 
not increased in the prolonged vs. the 
short-term thromboprophylaxis group. 
Major bleeding occurred in four (1.8%) 
patients in the short- term group and in 
one (0.5%) patient in the prolonged 
































• Er formålet klart formulert? YES 
• Var gruppene like ved starten? YES.  
• Hvem er inkludert/ekskludert? Both 
patients with cancer and with non-malignant 
surgeries were included.  
• Randomiseringsprosedyre? Computer-
generated random allocation in blocks of 10, 
stratified by center.  
• Ble deltakere/studiepersonell blindet mht 
gruppetilhørighet? Partly. The radiologist 
performing the venography was blinded. 
The patients either administrered Dalteparin 
for 1 or 4 weeks and thus were not blinded.   
• Ble gruppene behandlet likt utover 
«intervensjonen»? YES 
• Primære endepunktet – validert? 
(Classificatin bias?) YES.   
• Ble deltakernne gjort rede for på slutten 
av studien? (attrition/follow-up bias) 
YES. Patients were followed up for a period 
of minimum 2 months after venography. 
• Kan resultatene overføres til praksis? 
YES 
• Ble alle utfallsmål vurdert? YES 
• Er fordelene verdt ulemper/kostnader? 
YES 
• Annen litteratur som styrker resultatene? 
YES 
Styrke: 
- The robustness of the study was tested by an 
analysis that included randomized patients 
without a sound VTE endpoint. This 
analysis also showed a highly significant 
reduction in VTE with prolonged 
thromboprophylaxis.  
- Wide inclusion criteria to limit selection 
bias.  
Svakhet: 
- Preliminary results were published and might be 
source of bias.  
 




dalteparin, 5000 IU 
once daily, after 
major abdominal 
surgery significantly 
reduces the rate of 
VTE, without 
increasing the risk of 
bleeding, compared 




År data innsamling 
January 1997 – June 
2003 
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Referanse: 
Vedovati M BC, Rondelli F, Boncompagni M, Camporese G, Balzarotti R, et al. . A Randomized Study on 1-Week Versus 
4-Week Prophylaxis for Venous Thromboembolism After Laparoscopic Surgery for Colorectal Cancer. Annals of Surgery. 
2014;259(4):665-9. 
Studiedesign:  RCT                                
Grade - kvalitet    
Formål Materiale og metode Resultater Diskusjon/kommentarer/sjekkliste 
To compare the 
efficacy and safety of 
antithrombotic 
prophylaxis given for 1 
week or 4 weeks in 
patients undergoing 
laporascopic surgery 
for colorectal cancer.   
Rekruttering deltakere 
Consecutive patients who had undergone 
elective laparoscopic surgery for colorectal 
cancer in 5 hospitals in Italy were considered 
for inclusion.  
 
Inklusjons-/eksklusjonskrit. 
Patients with no evidence of VTE of the 
lower limbs after being examined with 
ultrasound 8± 2 days of antithrombotic 
prophylaxis were randomized.  
 
Patients were excluded in case of age < 18 
years, noncancer surgery, anticipated 
duration of surgery < 45 minutes, conversion 
from laporascopic to open surgery, other 
indications for anticoagulant treatment, 
major postsurgery complications leading to 
reoperation or bleeding before 
randomization, renal or hepatic failure, 
known cerebral metastasis, bleeding 
disorders, intracranial hemorhage or 
neurosurgery within the previous 6 months, 
known hypersensitivity for LMWH, previous 
heparininduced thrombocytopeni, pregnancy 
or lactation or refusal to participate 
 
Datagrunnlaget 
301 patients were evaluated for inclusion in 
the study and 225 were randomized. Study 
patients received antithrombotic prophylaxis 
for 8 ± 2 days starting on the evening before 
surgery.  
 
A complete compression ultrasonography of 
the venous system of the lower limbs was 
performed at day 8 ± 2 after surgery. Patients 
with no evidence of VTE were randomized 
to short (heparin withdrawal) or to extended 
(heparin continued for 3 additional weeks) 
prophylaxis in an open fashion.  
 
Utfall (outcome) validering 
The primary efficacy outcome was 
symptomatic VTE (deep vein thrombosis or 
pulmonary embolism) or deep vein 
thrombosis diagnosed at complete 
compression ultrasonography at day 28 ± 2 
from surgery. Computed tomography or 
pulmonary angiography or 
ventilation/perfusion lung scanning was done 
to confirm the clinical suspicion of 
pulmonary embolism.  
 
Statistiske metoder 
Data were reported as frequencies or means 
± SD according to variables. Continuous data 
were compared with the use of the t test. 
Categorical data were compared with use of 
either a χ 2 test or a Fisher exact test. The 
reported P values are based on 2-sided tests. 
To assess differences in the rates of VTE 
between the 2 treatment groups, the relative 
risk reduction and 95% confidence intervals 
(CIs) were calculated. Proportional hazards 
were calculated according to Cox regression 
statistics.   
Hovedfunn 
VTE occurred in 11 of 225 patients (4.9%, 95% CI: 
2.8%– 8.5%) from randomization to day 28 ± 2. All 
these events occurred in patients randomized to short 
heparin prophylaxis (11 of 113; 9.7%, 95% CI: 
5.5%–16.6%); no episode occurred in patients 
randomized to extended heparin prophylaxis (95% 
CI: 0%–3.3%) (P = 0.001). The study was 
interrupted after the results of the interim analysis 
were available and showed a reduction in the rate of 
VTE in patients assigned to extended heparin 
prophylaxis (P < 0.01).  
 
VTE was proximal or symptomatic deep vein 
thrombosis in 2 patients, both presenting with signs 
and symptoms suggestive of VTE before the 
scheduled day 28 ± 2 examination (Table 2). The 
remaining 9 venous thromboembolic events were 
asymptomatic distal deep vein thrombosis. No 
episodes of pulmunary embolism was observed. 
During the 3-month follow-up period, VTE was 
suspected in 1 patient randomized to extended 
prophylaxis and in none of those randomized to short 
prophylaxis.  
 
The overall 3-month incidence of VTE was 5.3% (12 
events out of 225 patients; 95% CI: 3.1%–9.1%) and, 
in particular, 9.7% (11 events out of 113 patients; 
95% CI: 5.5%–16.6%) in patients randomized to 
short heparin prophylaxis and 0.9% (1 out of 112; 
95% CI: 0.2%–4.9%) in patients randomized to 
extended heparin prophylaxis (relative risk 
reduction: 91%, 95% CI: 30%–99%; P = 0.005). 
None of the patients complained for signs or 
symptoms suggestive of pulmonary embolism during 
the 3-month follow-up.  
 
Bifunn 
At univariable analysis, age more than 70 years was 
a predictor of VTE (hazard ratio: 3.89, 95% CI: 
1.17–12.93; P = 0.02), and  
advanced cancer (stage IV according to TNM 
Classification of Malignant Tumours [TNM]) was 
associated with a higher but not statistically 
significant risk of VTE (hazard ratio: 3.2, 95% CI: 
0.42–24.90; P = 0.26). Age more than 70 years was 
confirmed to be an independent predictor of VTE at 
multivariable analysis (hazard  
ratio: 3.77, 95% CI: 1.13–12.55; P = 0.03).  
  
One patient randomized to short heparin prophylaxis 
experienced a major bleeding (intestinal bleeding 
with a blood loss of >20 g/L and requiring 
transfusions), and 1 patient randomized to extended 
prophylaxis experienced a clinically relevant 
nonmajor bleeding (rectal bleeding requiring heparin 
withdrawal) from randomization to day 28. The rate 
of major or clinically relevant nonmajor bleed- ing 





• Er formålet klart formulert? YES 
• Hvem er inkludert/ekskludert? Only 
cancer patients included.  
• Var gruppene like ved starten? 
Demographic features, risk factors for 
VTE, type and stage of cancer, and 
duration of surgery were similar in the 2 
study groups. 
• Randomiseringsprosedyre? A central 
randomization (1:1 short vs extended 
prophylaxis, in permuted blocks of 4, 
stratified according to study center) was 
used.  
• Ble deltakere/studiepersonell blindet 
mht gruppetilhørighet? The patients 
were not blinded, but the assessor was.  
• Ble gruppene behandlet likt utover 
«intervensjonen»? YES 
• Primære endepunktet – validert? 
(Classificatin bias?) YES 
• Ble deltakernne gjort rede for på 
slutten av studien? (attrition/follow-up 
bias) YES 
• Hva er resultatene? Presisjon? 
Prolonged prophylaxis reduces the risk of 
VTE.  
• Kan resultatene overføres til praksis? 
YES 
• Ble alle utfallsmål vurdert? YES 
• Er fordelene verdt ulemper/kostnader? 
YES 
• Annen litteratur som styrker 
resultatene? YES 
  
Hva diskuterer forfatterne som: 
-styrke 
-svakhet 
- This was a study with an open design; 
however, randomization was central and 
the operator who performed 
ultrasonography was blinded to treatment 
assignment.  
- The suboptimal sensitivity of 
ultrasonography as screening test for deep 
vein thrombosis could have 
underestimated the event rates.  
- The study was that patients received 
different types of LMWH for prophylaxis 
of VTE. All types and doses of LMWH 
used in this study were val- idated in the 
extended prophylaxis of VTE after major 
orthopedic surgery.  
 
Har resultatene plausible forklaringer? YES  
Konklusjon 
VTE occurred in 11 of 
113 patients 
randomized to short 
and in none of 112 
patients randomized to 
extended prophylaxis. 
The rate of bleeding 
complications was 
similar in the txo 
groups.   
Land 
Italy 
År data innsamling 
2010-2012 
 






Bergqvist D AG, Cohen A T, Eldor A, Nilsson P E, Moigne-Amrani A L, et al. . Duration of prophylaxis against 
venous thromboembolism with Enoxaparin after surgery for cancer. New English Medical Journal of Medicin. 
2002;346(13):975-80. 
Studiedesign:  RCT                                
Grade - kvalitet  Strong 
Formål Materiale og metode Resultater Diskusjon/kommentarer/sjekkliste 
To compare the efficacy of 
Enoksaparin to placebo for 
21 days extended 
antithrombotic prophylaxis.  
Inklusjons-/eksklusjonskrit. 
Eligible patients were 40 years of age or 
older, with a life expectancy of at least six 
months, and were scheduled to undergo open, 
elective, curative surgery for a malignant 
tumor of the gastrointestinal tract (other than 
the esophagus), genitourinary tract, or female 
reproductive organs. Procedures were 
performed with the patient under general 
anesthesia and with a planned duration of 
surgery of more than 45 minutes.  
 
The exclusion criteria were renal or hepatic 
insufficiency; known hypersensitivity to low-
molecular-weight heparin or radiographic 
contrast medium; cerebral thrombosis, 
cerebral hemorrhage, or neurosurgery within 
the previous six months; known cerebral 
metastases, generalized bleeding disorders, 
endo- carditis, or active peptic ulcer; venous 
thromboembolism within the previous three 
months; uncontrolled arterial hypertension; 
treatment with heparin compounds or oral 
anticoagulant agents within five days before 
surgery; and pregnancy or lactation.  
 
Datagrunnlaget 
Utfall (outcome) validering 
The primary efficacy end point was deep-vein 
thrombosis verified by venograms read by a 
central committee that was unaware of the 
patients’ treatment assignments, symptomatic 
pulmonary em- bolism confirmed by 
ventilation–perfusion lung scanning or 
pulmonary angiography, or both. Venography 
was performed routinely between days 25 and 
31. A clinical suspicion of venous thrombo- 
embolism before that time required objective 
testing and adjudi- cation by a central 
committee.  
 
The secondary efficacy end point was death 
from thromboembolic disease before three 
months, with sep- arate analyses of mortality 
during the three-week double-blind period 
and the two-month follow-up period.  The 
venographic results were evaluated and 
agreed on by the venography reading 
committee (consisting of three radiologists) 
before the investigators were unblinded. 
 
The primary safety end point was the 
occurrence of hemorrhage during the period 




Viktige konfunderende faktorer  
 
Statistiske metoder 
Categorical data were compared with use of 
either a chi-square test or Fisher’s exact test. 
The reported P values are based on two- sided 
tests. For the estimation and interpretation of 
differences be- tween the groups in the rates 
of venous thromboembolism, 95 per- cent 
confidence intervals were calculated. 
Hovedfunn 
During the double-blind period, the 
overall inci- dence of venous 
thromboembolism was 8.4 percent 
(28 of 332). In the group given one 
week of prophy- laxis (placebo 
group), the incidence was 12.0 
percent (20 of 167); in the group 
given four weeks of prophy- laxis, it 
was 4.8 percent (8 of 165) (P=0.02). 
This corresponds to a reduction in 
risk of 60 percent (95 per- cent 
confidence interval, 10 to 82 
percent). Proximal deep-vein 
thrombosis was identified in three 
patients in the placebo group and 
one in the enoxaparin group  
 
Bifunn – andre viktige 
endepunkter 
There were no significant 
differences between the groups in 
the incidence of major or minor 
bleeding during the double-blind 
period or the two-month follow-up 
period.  
 



































• Er formålet klart formulert? YES 
• Hvem er inkludert/ekskludert? 
Patients with cancer were included.  
• Var gruppene like ved starten?  The 
patients in the two groups were well 
matched at baseline with regard to 
demographic variables, risk factors, and 
the type and duration of surgery  
• Randomiseringsprosedyre?  
Randomization was stratified according 
to the country where the institution was 
located. All patients randomly assigned 
to enoxaparin or placebo after the first 
week of therapy. 
• Ble deltakere/studiepersonell blindet 
mht gruppetilhørighet? YES 
• Ble gruppene behandlet likt utover 
«intervensjonen»? YES 
• Primære endepunktet – validert? 
(Classificatin bias?) YES 
• Ble deltakernne gjort rede for på 
slutten av studien? (attrition/follow-
up bias) YES 
• Hva er resultatene? Presisjon? 
Prolonged prophylaxis reduces the risk 
of VTE.  
• Kan resultatene overføres til praksis? 
YES. For cancer patients only.  
• Ble alle utfallsmål vurdert? YES 
• Er fordelene verdt 
ulemper/kostnader? YES. NNT 14.  
• Annen litteratur som styrker 
resultatene? YES 
 
 Hva diskuterer forfatterne som: 
-styrke 
-svakhet 
Approximately one third of the patients did not 
undergovenography or had an uninterpretable 
venogram.  
 
Har resultatene plausible forklaringer? YES 
Konklusjon 
Enoxaparin prophylaxis for 
four weeks after surgery for 
abdominal or pelvic cancer 
is safe and significantly 
reduces the incidence of 
venograph- ically 
demonstrated thrombosis, as 
compared with enoxaparin 
prophylaxis for one week.  
Land 
Denmark, France, Greece, 
Isreal, Italy, Sweden, 
Switzerland and the United 
Kingdom.  
År data innsamling 
1998-2000 
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Vendler MM I HT, Waage JE, Kleif J, Kristensen B, Gögenur I, et al. Incidence of venous thromboembolic events in 
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Studiedesign: Population based study 
Grade - kvalitet   Moderate 
Formål Materiale og metode Resultater Diskusjon/kommentarer/sjekkliste 
To describe the risk of venous 
thromboembolism (VTE) and 
estimate the cost of preventing 
one case of VTE by prolonged 
thromboseprofylaxis (PT) 
under Enhanced Recovery 
After Surgery (ERAS).   
Populasjon: 
Patients undergoing elective surgery for colon 
cancer Stage I-III in the Capital Region of 
Denmark, 1 June 2008 to 31 December 2013. 
 
Patients not eligible for prolonged low-dose 
LMWH VTE prophylaxis were excluded 
according to the fol- lowing criteria: 
- Group 1. Patients, who died before 
discharge from hospital or were 
discharged at postoperative day 28 
or later. These patients received 
LMWH until the time of death or 
discharge and are not relevant 
according to the guidelines in 
question.  
- Group 2. Patients already on 
prophylaxis with vita- min K 
antagonists (VKA), LMWH or new 
oral anti- coagulants (NOAC) 
before surgery and with continued 
prophylaxis afterwards were 
excluded from the analyses. This 
concurrent use was considered 
equivalent to, or more effective 
than, the prolonged low-dose 
LMWH VTE prophylaxis 
recommended in the guidelines. As 
such, patients were not included if 
they had a VTE less than 3 months 
before the resec- tion, as they were 
treated with one of the drugs men- 
tioned above.  
Hovedutfall: 
Primary outcome was the incidence of 
symptomatic VTE within 60 days after 
surgery. The secondary outcome was the cost 
of prolonged thromboprophylaxis with 
LMWH to prevent one symptomatic VTE. A 
sen- sitivity analysis of the primary outcome 
was performed, with deaths of unknown 
causes assumed to be VTE-related.  
 
Statistiske metoder 
Continuous data are presented as median 
[interquartile range (IQR)] values, and 
categorical data are presented as n (%). All 
statistical analyses were carried out using R 




In the study group, four (0.21%; 95% CI: 
0.07– 0.58) of 1893 patients discharged 
within 28 days of surgery and without 
prolonged VTE prophylaxis had a 
symptomatic VTE diagnosed during the first 
60 postoperative days of colon resection.  
 
As a result of the small number of VTEs, 
identification of risk factors using a 
multivariable logistic regression analysis was 




If we assume that the risk is equivalently 
reduced for symptomatic and asymptomatic 
VTEs and that the effect of prolonged VTE 
prophylaxis is a 60% reduction of the risk of 
VTE, the number needed to treat can be 
calculated. The number of VTE events in 
1893 patients would decrease from 4 to 1.6 
and the number needed to treat would be 
789. If the three deaths from unknown causes 
within 90 days of surgery were caused by 
VTE, the number needed to treat is reduced 
to 451.  
The cost of each VTE prevented is estimated 
to be 517 660– 954 890 kr (Danish kroner), 






























• Er formålet klart formulert? YES 
• Var studien basert på et tilfeldig utvalg 
fra en egnet pasientgruppe? YES 
• Var inklusjonskriteriene klart 
definert? YES 
• Var alle pasientene i samme stadium av 
sykdommen? NO 
• Var responseraten høy nok? 
Frafallsanal.? YES 
• Ble det brukt objektive kriterier for å 
vurdere/validere endepunktene? YES 
• Er prognostiske/konfunderende 
faktorer beskrevet tatt hensyn til i 
design/anal? YES 
• Var registreringen prospektiv? NO, 
retrospecitve.  
• Var oppfølgningen lang nok? Maybe. 
The longer the follow-up, the bigger the 
risk for other risk factor to contribute.  
• Var oppfølgningen tilstrekkelig for å nå 
endepunktene? YES 
• Stoler du på resultatene? YES 
• Kan resultatene overføres til praksis? 
YES 
• Annen litteratur som støtter 
resultatene? YES 
  
Hva diskuterer forfatterne som: 
Styrke: 
Population-based studies might be biased by 
misclassification if the data on medication are based 
on diagnoses or on prescriptions drawn from 
registers. To strengthen our study, we reviewed the 
medical records of all patients regarding 
anticoagulant defined as VKA, NOAC or LMWH. 
This enabled us to decrease the potential risk of 
selection bias by excluding only patients receiving 
VKA, NOAC or LMWH. This review also increased 
the validity of the outcome (i.e. symptomatic VTE).  
 
Svakhet: 
As a result of the retrospective design, some symp- 
tomatic VTEs may potentially have been missed, but 
because treatment of all acute cases of VTE in 
Denmark is managed within the public health 
system, the risk is very low.  
The minor differences in the ERAS protocols 
between the participating centres are a limitation, but 
the effect seems to be negligible because of the low 
risk of VTE found in the present study.  
Another limitation is that the end point is 
symptomatic VTEs only.  
Har resultatene plausible biologiske forklaringer? 
YES  
Konklusjon 
The risk of symptomatic VTE 
after uncomplicated, elective 
surgery for colon cancer with 
ERAS seems negligible and 
the cost-effectiveness of PT to 
prevent one symptomatic VTE 
seems questionable.   
Land 
Denmark 
År data innsamling 
2008-2013 
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Formål Materiale og metode Resultater Diskusjon/kommentarer/sjekkliste 
To compare the incidence of 
VTE after laparoscopic and 




Patients from the University Health System 
Consortium (UCH) database who were 18 
years or older and who underwent 1 of 4 
commonly performed gastrointestinal 
procedures - appendectomy, cholecystectomy, 
antireflux surgery, and Roux- en-Y gastric 
bypass. These 4 procedures were selected 
because they have both the laparoscopic and 
open ICD-9 procedural codes for their 
respective procedures.  
 
Kohorter 
Patients that underwent laparoscopic compared 
with open appendectomy, cholecystectomy, 





The principal outcome measure was the 
incidence of venous thrombosis or pulmonary 
embolism occurring during the initial 
hospitalization after laparoscopic and open 
surgery.  
 
The diagnosis of venous thrombosis and PE 
during the hospitalization for laparoscopic and 
open surgery was based on the presence of a 
secondary diagnosis of an ICD-9 CM code for 
venous thrombosis and/or PE.  
 
 
Viktige konfunderende faktorer  
Statistiske metoder 
Data was expressed as mean  SD. Differences 
in patient characteristics and VTE between 
laparoscopic versus open group were analyzed 
using Fisher exact test or the Pearson’s 
2 
test. Univariate analysis was performed and 
the 95% confidence interval (CI) of the odds 
ratio (OR) was obtained. Continuous variables 
were compared using Student t tests. Statistical 
analysis was performed using Epi Info 
statistical software, version 3.3.2 (CDC, 
Atlanta, GA). A P value of less than 0.05 was 





Overall, VTE was diagnosed during the 
index hospitalization in 259 of 92,490 
(0.28%) laparoscopic cases and 271 of 
46,105 (0.59%) open cases.  
 
Univariate analysis showed that open 
surgery was a significant factor for 
development of VTE even when 
stratified according to different level of 
severity of illness; for minor/moderate 
severity of illness level the OR was 
1.83 (95% CI: 1.32–2.54) and for 
major/extreme severity of illness level 
the OR was 1.31 (95% CI: 1.06 –1.62).  
Laparoscopic appendectomy was 
associated with a lower rate of VTE 
compared with open appendectomy 
(0.11% vs. 0.28%, P < 0.01). 
Laparoscopic cholecystectomy was 
associated with a lower rate of VTE 
compared with open cholecystectomy 
(0.36% vs. 1.03%, P < 0.01) and 
persisted when stratified according to 
different severity of illness level; for 
minor/moderate severity of illness level 
the OR was 1.99 (95% CI: 1.20–3.27) 
and for major/extreme severity of 
illness level the OR was 1.35 (95% CI: 
1.04– 1.74).  
Laparoscopic antireflux surgery was 
associated with a lower rate of VTE 
com- pared with open antireflux 
surgery (0.09% vs. 1.1%, P < 0.01) and 
persisted when stratified according to 
minor/mod- erate severity of illness 
level with an OR of 24.66 (95% CI: 
2.61–580.87).  
Laparoscopic gastric bypass was 
associated with a lower rate of VTE 
compared with open gastric bypass 
(0.30% vs. 0.78%, P < 0.01) and 
persisted when stratified according to 
minor/moderate severity of illness level 








  Sjekkliste:  
• Formålet klart formulert? YES 
• Er gruppene rekruttert fra samme 
populasjon/befolkningsgruppe? YES 
• Var gruppene sammenliknbare i forhold til 
viktige bakgrunnsfaktorer? (seleksjons bias) 
No. There was difference in the severity of 
illness between the 2 groups.  
• Var de eksponerte individene representative 
for en definert 
befolkningsgruppe/populasjon? NO 
• Ble eksposisjon og utfall målt likt og pålitelig 
(validert) i de to gruppene? YES.  
• Er den som vurderte resultatene 
(endepunktene) blindet for 
gruppetilhørighet? No.  
• Var studien prospektiv? The study was 
retrospective.  
• Ble mange nok personer i kohorten fulgt 
opp? YES 
• Var oppfølgingstiden lang nok til å påvise 
positive og/eller negative utfall? NO. Only in-
hospital data.  
• Er det tatt hensyn til viktige konfunderende 
faktorer i design/ gjennomføring/analyser? 
NO.  
• Tror du på resultatene? YES  
• Kan resultatene overføres til den generelle 
befolkningen? NO 
• Annen litteratur som styrker/svekker 
resultatene? YES 
• Hva betyr resultatene for endring av praksis? 
The study is not good enough to change 
practice.  
    
Hva diskuterer forfatterne som: 
Svakhet:  
A weakness in comparing the outcome of laparoscopic 
versus open procedure is the limited use of risk-adjustment 
in most databases. An argument against the validity of the 
results in this study is that open procedures were performed 
in higher risk patients with more comorbidity.  
There is no information available on the use or nonuse of 
thromboprophylaxis or about the type (mechanical or 
antithrombotics) and duration of prophylaxis.  
Another limitation is that the data used in this study were 
obtained from an administrative database that does not have 
any information concerning the use or nonuse of 
thromboprophylaxis or the type and duration of the 
prophylaxis. There is also lack of information about the 
physiologic status of the patient and history for venous 
thrombosis or PE, and lack of body mass index for risk 
stratification in the morbidly obese patients.  
Additionally, the UHC database is compiled from discharge 
abstract data and is limited to in-hospital morbidity only 
without follow-up data. Therefore, VTE arising after 
discharge would not be captured in this database and we do 




Within the context of this large 
administrative clinical data set, 
the frequency of perioperative 
VTE is lower after laparo- 
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